Biogen, Isis unite for the 4th time to develop neurological drugs

09/10/2013 | Reuters · Genetic Engineering & Biotechnology News

Biogen Idec signed a deal with Isis Pharmaceuticals to develop new treatments for neurological diseases using the latter's antisense technology. The current deal, which entitles Isis to $100 million upfront, is the fourth collaboration between the firms in the past two years. Isis will get milestone and licensing fees plus sales royalties on products arising from the collaboration.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN